• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Semaglutide associated with dose-dependent weight loss and resolution of nonalcoholic steatohepatitis

byThomas SuandDeepti Shroff Karhade
November 22, 2020
in Chronic Disease, Endocrinology, Gastroenterology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Nonalcoholic steatohepatitis (NASH) resolution without worsening of fibrosis occurred in a significantly greater percentage of patients who received semaglutide versus placebo, but the number of patients who had improvement in fibrosis without worsening of NASH was similar between groups.

2. Patients who received semaglutide lost 8-20x more weight (depending on dose) than those who received placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Nonalcoholic steatohepatitis (NASH) is an aggressive form of fatty liver disease that is associated with fibrosis and cirrhosis as well as cardiovascular disease, chronic renal disease, and cancer. No specific pharmacotherapies currently exist for NASH, so treatment is limited to weight loss and management of coexisting conditions. Given that insulin resistance is known to be a key pathogenic driver of NASH, a number of glucagon-like peptide-1 (GLP-1) agonists are currently being investigated for their liver-specific effects. Semaglutide, one such agent, has previously been shown to facilitate reductions in body weight, transaminase levels, and various biomarkers of inflammation. In this phase 2 trial, patients were administered subcutaneous semaglutide at 3 different dosages and monitored for histological changes in liver tissue. Among patients with stage F2 or F3 fibrosis, semaglutide at all dosages resulted in a greater likelihood of NASH resolution compared to placebo. However, the percentage of these patients who experienced an improvement of at least 1 point in fibrosis stage was similar across all groups. Over twice as many patients in the 0.4-mg group achieved both of these endpoints as compared to the placebo group; conversely, worsening of fibrosis occurred in nearly twice as many patients in the placebo group versus the 0.1-mg group, which had the highest frequency of the three semaglutide groups. Further, patients in the semaglutide groups experienced greater, dose-dependent reductions in alanine- and aspartate-aminotransferase levels versus placebo. Lastly, gastrointestinal adverse events and serious adverse events were dose-independent but occurred in a greater percentage of patients in the three treatment groups versus placebo.

Click here to read the study in NEJM

Relevant Reading: Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers

In-Depth [randomized controlled trial]: This double-blinded, multicenter phase 2 trial conducted from January 2017 to September 2018 involved 320 adults under 75 years of age who had a BMI >25 kg/m2, histological evidence of NASH (NAFLD activity score >4 with at least 1 point in each category: steatosis, lobular inflammation, hepatocyte ballooning), and a fibrosis stage of F1, F2, or F3. Study participants were stratified by geography (Japan vs. other), type 2 diabetes status, and fibrosis stage (F1 or F2 vs. F3) and randomly assigned in a 3:3:3:1:1:1 ratio to receive once-daily subcutaneous semaglutide at a dose of 0.1, 0.2, or 0.4 mg or corresponding placebo. Semaglutide was initiated at 0.05 mg/day, increased to 0.1 mg/day after 4 weeks, and then increased by 0.1 mg/day every 4 weeks thereafter until the target dose had been reached. After 72 weeks, a significantly greater percentage of patients with stage F2 or F3 fibrosis in all three treatment groups reached the primary endpoint—resolution of NASH (defined as no more than mild residual inflammation and no hepatocyte ballooning) with no worsening of liver fibrosis. The between-group difference compared to placebo was smaller in the 0.1-mg group (odds ratio [OR], 3.36; 95% CI, 1.29-8.86) and 0.2-mg group (OR, 2.71; 95% CI, 1.06-7.56) and largest in the 0.4-mg group (59% vs. 17%; OR, 6.87; 95% CI, 2.60-17.63; P<0.001). All four groups were similar with respect to the percentage of patients who reached the confirmatory secondary endpoint—an improvement of at least one fibrosis stage with no worsening of NASH.

RELATED REPORTS

Non-alcoholic fatty liver disease-related hepatocellular carcinoma (HCC) differ clinically compared to HCC due to other causes

Semaglutide and phentermine-topiramate are effective weight reducing medications

#VisualAbstract: Combined cagrilintide and semaglutide for weight management well-tolerated in early clinical trials

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: non-alcoholic fatty liver disease (NAFLD)Non-alcoholic steatohepatitis (NASH)semaglutide
Previous Post

Plant-based QVLP influenza vaccine likely non-inferior to commercial inactivated vaccines

Next Post

2 Minute Medicine Rewind November 23, 2020

RelatedReports

Patient Basics: Liver Cancer
Oncology

Non-alcoholic fatty liver disease-related hepatocellular carcinoma (HCC) differ clinically compared to HCC due to other causes

March 14, 2022
Many new pediatric asthma cases attributable to obesity
Chronic Disease

Semaglutide and phentermine-topiramate are effective weight reducing medications

February 2, 2022
#VisualAbstract: Primary trabeculectomy vs. medical management for advanced glaucoma have similar outcomes
StudyGraphics

#VisualAbstract: Combined cagrilintide and semaglutide for weight management well-tolerated in early clinical trials

May 27, 2021
Sleep duration inversely related to childhood type 2 diabetes risk makers
Chronic Disease

Combined cagrilintide and semaglutide for weight management well-tolerated in early clinical trials

May 20, 2021
Next Post
Parents often unaware of adolescents’ suicidal thoughts

2 Minute Medicine Rewind November 23, 2020

Febuxostat not effective at delaying progression of carotid atherosclerosis in asymptomatic hyperuricemia

Evinacumab may be effective in reducing lipid levels in patients with refractory hypercholesterolemia

Screening and exercise interventions did not reduce fractures in the elderly

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Wellness Check: Sleep
  • Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events
  • Early onset Lewy Body Dementia is more clinically distinct from Alzheimer Dementia than late onset Lewy Body Dementia
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.